To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

JW Pharmaceutical155 enrolled

Overview

A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.

Multicenter, randomized, double-blind, parallel-design, phase III clinical study

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

155

Conditions

Dyslipidemia Hypertension

Interventions

LivaloVADRUG

For 8 weeks(PO, QD)

LivaloVDRUG

For 8 weeks(PO, QD)

VADRUG

For 8 weeks(PO, QD)

Eligibility

Sex: ALLMin age: 19 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with hypertension and dyslipidemia Exclusion Criteria: * The subject not meet the specified msBP and LDL-C level

Locations (1)

Gangdong Sacred Heart Hospital

Seoul, Korea, South Korea

Outcomes

Primary Outcomes

msSBP (8 weeks) lowering effect, LDL-C (8 weeks) lowering effect

change in msSBP and LDL-C level

Time frame: week 8

Secondary Outcomes

efficacy and safety

change in msSBP and LDL-C level

Time frame: week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.